A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia
NCT ID: NCT01212575
Last Updated: 2011-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
186 participants
OBSERVATIONAL
2010-10-31
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia
NCT00833456
The Sub-Sero Study
NCT03994965
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
NCT01160679
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05958875
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
NCT00809731
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
300 patients
Female or male aged 18-65 years with a diagnosis of schizophrenia having received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eva Dencker Vansvik
Role: STUDY_DIRECTOR
AstraZeneca Nordic-Södertälje, Sweden
Charlotte Emborg
Role: PRINCIPAL_INVESTIGATOR
Skovager 2, Risskov, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aabenraa, Aabenraa, Denmark
Research Site
Aarhus, Arhus, Denmark
Research Site
Arhus N, Arhus, Denmark
Research Site
Arhus S, Arhus, Denmark
Research Site
Ballerup Municipality, Ballerup, Denmark
Research Site
Cph NV, Cph, Denmark
Research Site
Cph N, Cph, Denmark
Research Site
Esbjerg, Esbjerg, Denmark
Research Site
Haderslev, Haderslev, Denmark
Research Site
Hillerød, Hillerod, Denmark
Research Site
Middelfart, Middelfart, Denmark
Research Site
Rønde, Ronde, Denmark
Research Site
Tønder, Tonder, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Emborg C, Hallerback T, Jorgensen L, Carlborg A. A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark. Hum Psychopharmacol. 2012 Sep;27(5):492-8. doi: 10.1002/hup.2254.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-NDK-SER-2010/2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.